Officials Cast Doubt on a Dementia Drug, but Human Trials Continue

The S.E.C. alleged shortcomings in research said to support the drug, and its developer agreed to a $40 million settlement. Some experts wonder why clinical trials have not been stopped.

source https://www.nytimes.com/2024/10/02/health/alzheimers-simufilam-cassava-sciences.html